The Food and Drug Administration has approved Zoryve (roflumilast) topical foam, 0.3% for plaque psoriasis of the scalp and body.

For patients with psoriasis receiving biologic therapy, residual inflammation (RI), defined as increased inflammatory markers in blood, characterized by high-sensitivity C-reactive protein, despite ...

The researchers found that 36.3% of patients had residual inflammation. (HealthDay News) — For patients with psoriasis receiving biologic therapy, residual inflammation (RI), defined as ...

WEDNESDAY, May 21, 2025 (HealthDay News) -- For patients with psoriasis receiving biologic therapy, residual inflammation (RI), defined as increased inflammatory markers in blood, characterized by ...

SAN DIEGO — Disease-modifying antirheumatic drugs (DMARDs) and biologics were linked to as much as a 74.5% reduction in the risk for alopecia areata (AA) in patients with psoriasis, a new ...

In 2022, a drug called deucravacitinib was approved by the U.S. Food and Drug Administration to treat psoriasis. This medication targets TYK2 in a way that stops its ability to relay harmful ...

Biologic treatment costs for plaque psoriasis more than doubled from 2007 to 2021, despite cheaper alternatives. Switching to the lowest-cost biologic in each class could reduce treatment costs by ...

Patients with moderate to severe psoriasis treated with ustekinumab ... Research Database during 2011-2021 who were treated with biologics (6769 patients) or traditional systemic treatments ...

A study published in JAAD assessed the rates of suicidal and self-injurious behaviors (SSIBs) among patients with psoriasis or psoriatic arthritis treated with biologics. The results showed that ...

BRIDGEWATER, N.J., and BENGALURU, India, March 7, 2025 /PRNewswire/ -- Biocon Biologics Ltd. (BBL ... with moderate to severe chronic plaque psoriasis (PsO). The data are being presented ...

It is known that 25%–30% of individuals with cutaneous psoriasis (PsC) will develop psoriatic arthritis ... PsA to only healthy participants or other forms of arthritis. The flow chart in figure 1 ...

Interleukin-23 inhibitors, prior treatment history, and Psoriasis Area and Severity Index scores may be predictive of time to disease relapse among patients with psoriasis who achieved clinical ...